Drugs / TRIPLATIN TETRANITRATE
TRIPLATIN TETRANITRATE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00024362 | May 2001 → ? | malignant pancreatic neoplasm | Theradex | Unknown | No outcome recorded |
| Phase 2 | NCT00014547 | Nov 2000 → ? | lung cancer | Theradex | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRIPLATIN TETRANITRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297208 ↗ |
| Known as | BBR 3464 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00014547 ↗ |
| Known as | Tetranitrate de triplatine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297208 ↗ |
| Known as | Tetranitrato de triplatino | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297208 ↗ |
| Modality | Small molecule | — CHEMBL4297208 ↗ |
| Route | Intravenous | “Patients receive BBR 3464 IV over 1 hour on day 1.” NCT00014547 ↗ |